Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
William Rote, Ph.D., chief research officer plans to retire in early 2027
Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and be named executive vice president, head of research and development and CMO.
“On behalf of the Board of Directors and everyone at Travere, I want to thank Bill for his extraordinary leadership, scientific vision and unwavering commitment to patients over the last decade,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease. He built and strengthened critical research and development capabilities, assembled exceptional teams across his organization, and helped to guide successful approvals in both IgA nephropathy and focal segmental glomerulosclerosis. His contributions have left an enduring mark on Travere and, most importantly, on the patients we serve.”
